Review



human her2 female breast cancer cell lines bt474 ts  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC human her2 female breast cancer cell lines bt474 ts
    Human Her2 Female Breast Cancer Cell Lines Bt474 Ts, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 3998 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cells+bt474/BT-474/pm42115409-59-0-19
    Average 99 stars, based on 3998 article reviews
    human her2 female breast cancer cell lines bt474 ts - by Bioz Stars, 2026-09
    99/100 stars

    Images

    Related Articles

    Multiple Displacement Amplification:

    Article Title: Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism
    Article Snippet: .. Cell lines and cell cultures The breast cancer cells BT474, SKBR3, ZR-7530, and MDA-MB-361 were purchased from ATCC and used within 6 months. .. BT474, SKBR3 and MDA-MB-361 cells were cultured in DMEM/F-12 (Mediatech Inc.) with 10% FBS.

    Article Title: Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism
    Article Snippet: .. The breast cancer cells BT474, SKBR3, ZR-7530, and MDA-MB-361 were purchased from ATCC and used within 6 months. .. BT474, SKBR3 and MDA-MB-361 cells were cultured in DMEM/F-12 (Mediatech Inc.) with 10% FBS.

    Expressing:

    Article Title: Antibody binding to human HER2 and preparation method and use thereof
    Article Snippet: Such methods are well known to those of ordinary skill in the art, and are described in many publications, including Sambrook, J., Fritsch, E. F. and Maniais, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd edition, Cold spring Harbor Laboratory Press. .. The cell lines with high HER2 expression used in the following examples included breast cancer cells BT474, breast cancer cells SKBR3, gastric cancer cells NCI-N87, and breast cancer cells HCC1954, wherein HCC1954 (Catalog No.: ATCC® CRL-2338TM) and SKBR3 (Catalog No.: ATCC® HTB-30TM) were purchased from the American Type Culture Collection (ATCC), BT474 (Catalog No.: TCHu143) and NCI-N87 (Catalog No.: SCSP-534) were purchased from the Cell Bank of the Chinese Academy of Sciences, and they were cultured according to the corresponding instructions. .. The positive control antibodies used in the following examples was Herceptin (purchased from Roche, 440 mg/20 ml, Lot No. N3723) and Perjeta (purchased from Roche, 420 mg/14 ml, Lot No. H0248B02).

    Cell Culture:

    Article Title: Antibody binding to human HER2 and preparation method and use thereof
    Article Snippet: Such methods are well known to those of ordinary skill in the art, and are described in many publications, including Sambrook, J., Fritsch, E. F. and Maniais, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd edition, Cold spring Harbor Laboratory Press. .. The cell lines with high HER2 expression used in the following examples included breast cancer cells BT474, breast cancer cells SKBR3, gastric cancer cells NCI-N87, and breast cancer cells HCC1954, wherein HCC1954 (Catalog No.: ATCC® CRL-2338TM) and SKBR3 (Catalog No.: ATCC® HTB-30TM) were purchased from the American Type Culture Collection (ATCC), BT474 (Catalog No.: TCHu143) and NCI-N87 (Catalog No.: SCSP-534) were purchased from the Cell Bank of the Chinese Academy of Sciences, and they were cultured according to the corresponding instructions. .. The positive control antibodies used in the following examples was Herceptin (purchased from Roche, 440 mg/20 ml, Lot No. N3723) and Perjeta (purchased from Roche, 420 mg/14 ml, Lot No. H0248B02).



    Similar Products

    99
    ATCC human her2 female breast cancer cell lines bt474 ts
    Human Her2 Female Breast Cancer Cell Lines Bt474 Ts, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cells+bt474/BT-474/pm42115409-59-0-19
    Average 99 stars, based on 1 article reviews
    human her2 female breast cancer cell lines bt474 ts - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    ATCC bt474 breast cancer cell lines
    Bt474 Breast Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cells+bt474/BT-474/pm41231242-225-15-23
    Average 99 stars, based on 1 article reviews
    bt474 breast cancer cell lines - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    ATCC human breast cancer cell line bt474
    Human Breast Cancer Cell Line Bt474, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cells+bt474/BT-474/pm41106321-279-5-21
    Average 99 stars, based on 1 article reviews
    human breast cancer cell line bt474 - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    ATCC bt474 breast cancer cell line
    Bt474 Breast Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cells+bt474/BT-474/pm40939536-404-1-33
    Average 99 stars, based on 1 article reviews
    bt474 breast cancer cell line - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    ATCC epidermal growth factor receptor 2 positive human bt474 breast cancer cell line
    Penetration data in <t>BT474</t> spheroids (200-µm radius) for Alexa Fluor 647-NHS-trastuzumab ( ), CFDA-SE liposomes ( ), and CFDA-SE liposomes after preirradiating spheroids with 6.5 kBq/mL 225 Ac-trastuzumab ( ). Shown are time-integrated average concentrations as function of distance from centers of spheroids (A) and correlated mean decays per cell using activity concentrations of 6.875 kBq/mL for all drugs (calculated with MIRDcell-Ã) (B). Distances beyond 200 µm represent medium.
    Epidermal Growth Factor Receptor 2 Positive Human Bt474 Breast Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cells+bt474/BT-474/pmc12320574-16-5-19
    Average 99 stars, based on 1 article reviews
    epidermal growth factor receptor 2 positive human bt474 breast cancer cell line - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    ATCC breast cancer cells bt474
    Penetration data in <t>BT474</t> spheroids (200-µm radius) for Alexa Fluor 647-NHS-trastuzumab ( ), CFDA-SE liposomes ( ), and CFDA-SE liposomes after preirradiating spheroids with 6.5 kBq/mL 225 Ac-trastuzumab ( ). Shown are time-integrated average concentrations as function of distance from centers of spheroids (A) and correlated mean decays per cell using activity concentrations of 6.875 kBq/mL for all drugs (calculated with MIRDcell-Ã) (B). Distances beyond 200 µm represent medium.
    Breast Cancer Cells Bt474, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cells+bt474/BT-474/us12319748-134-13-34
    Average 99 stars, based on 1 article reviews
    breast cancer cells bt474 - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    90
    China Center for Type Culture Collection human breast cancer cell line bt474
    Penetration data in <t>BT474</t> spheroids (200-µm radius) for Alexa Fluor 647-NHS-trastuzumab ( ), CFDA-SE liposomes ( ), and CFDA-SE liposomes after preirradiating spheroids with 6.5 kBq/mL 225 Ac-trastuzumab ( ). Shown are time-integrated average concentrations as function of distance from centers of spheroids (A) and correlated mean decays per cell using activity concentrations of 6.875 kBq/mL for all drugs (calculated with MIRDcell-Ã) (B). Distances beyond 200 µm represent medium.
    Human Breast Cancer Cell Line Bt474, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cells+bt474/bt474+cells/pm40480079-362-1-12
    Average 90 stars, based on 1 article reviews
    human breast cancer cell line bt474 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    99
    ATCC bt474 human breast cancer cells
    Figure 2. Characterization of Lapatinib-resistant <t>BT474</t> cell variants. (A) Cell viability was evaluated by the MTT assay; BT474 (parental), BT474LapRV1, and BT474LapRV2 cells were treated with increasing concentrations of Lap for 48 h. Each data point is the mean of three independent experiments ± SD. IC50 values for Lap treatment. (B) Colony formation assay of parental and Lap-resistant BT474LapRV1
    Bt474 Human Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cells+bt474/BT-474/pm40332401-423-1-6
    Average 99 stars, based on 1 article reviews
    bt474 human breast cancer cells - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    Image Search Results


    Penetration data in BT474 spheroids (200-µm radius) for Alexa Fluor 647-NHS-trastuzumab ( ), CFDA-SE liposomes ( ), and CFDA-SE liposomes after preirradiating spheroids with 6.5 kBq/mL 225 Ac-trastuzumab ( ). Shown are time-integrated average concentrations as function of distance from centers of spheroids (A) and correlated mean decays per cell using activity concentrations of 6.875 kBq/mL for all drugs (calculated with MIRDcell-Ã) (B). Distances beyond 200 µm represent medium.

    Journal: Journal of Nuclear Medicine

    Article Title: Preirradiation of Spheroids with 225 Ac-Trastuzumab Improves Penetration of 225 Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails

    doi: 10.2967/jnumed.124.269273

    Figure Lengend Snippet: Penetration data in BT474 spheroids (200-µm radius) for Alexa Fluor 647-NHS-trastuzumab ( ), CFDA-SE liposomes ( ), and CFDA-SE liposomes after preirradiating spheroids with 6.5 kBq/mL 225 Ac-trastuzumab ( ). Shown are time-integrated average concentrations as function of distance from centers of spheroids (A) and correlated mean decays per cell using activity concentrations of 6.875 kBq/mL for all drugs (calculated with MIRDcell-Ã) (B). Distances beyond 200 µm represent medium.

    Article Snippet: The spheroids comprised the human epidermal growth factor receptor 2–positive human BT474 breast cancer cell line, obtained from the American Type Culture Collection.

    Techniques: Liposomes, Activity Assay

    MIRDcell calculated mean decays per cell attributed to liposomes in BT474 spheroids based on experimental CFDA-SE liposome penetration data for (100% 225 Ac-liposome case from Howe et al. ) and (50% 225 Ac-liposome, 50% 225 Ac-trastuzumab case from newly retrieved data), and extrapolated/averaged (weighted) liposome penetration data for (70% 225 Ac-liposome, 30% 225 Ac-trastuzumab case) and (30% 225 Ac-liposome, 70% 225 Ac-trastuzumab case).

    Journal: Journal of Nuclear Medicine

    Article Title: Preirradiation of Spheroids with 225 Ac-Trastuzumab Improves Penetration of 225 Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails

    doi: 10.2967/jnumed.124.269273

    Figure Lengend Snippet: MIRDcell calculated mean decays per cell attributed to liposomes in BT474 spheroids based on experimental CFDA-SE liposome penetration data for (100% 225 Ac-liposome case from Howe et al. ) and (50% 225 Ac-liposome, 50% 225 Ac-trastuzumab case from newly retrieved data), and extrapolated/averaged (weighted) liposome penetration data for (70% 225 Ac-liposome, 30% 225 Ac-trastuzumab case) and (30% 225 Ac-liposome, 70% 225 Ac-trastuzumab case).

    Article Snippet: The spheroids comprised the human epidermal growth factor receptor 2–positive human BT474 breast cancer cell line, obtained from the American Type Culture Collection.

    Techniques: Liposomes

    Comparison of BT474 experimental outgrowths taken from Howe et al. to MIRDcell (version 4.14)-predicted SFs as bar plot (A), linear regression plot (B), and Bland–Altman plot (C) (95% limit of agreement, −0.048 to 0.095). Predicted SFs shown were based on 225 Ac-trastuzumab in spheroids with no 225 Ac daughters present and 225 Ac-liposomes in spheroids with 225 Ac daughters present. 225 Ac-trastuzumab and 225 Ac-liposomes in medium both had 225 Ac daughters present. Bars on abscissa of panel A and legend for panels B and C are labeled to denote percentage of activity corresponding to 225 Ac-liposomes and 225 Ac-trastuzumab. For example, “L-100, A-0” is 100% 225 Ac-liposomes and 0% activity on trastuzumab antibodies. Error bars for experimental outgrowths correspond to SD. Final prediction uses penetration data for CFDA-SE liposomes after spheroids are exposed to 6.5 kBq/mL 225 Ac-trastuzumab for 50%/50% case; 70% and 30% 225 Ac-liposome cases use extrapolated/averaged penetration data shown in . For CFDA-SE liposomes, published penetration data that were used for old prediction did not involve pretreatment 225 Ac-trastuzumab. Only final predictions are shown in panels B and C.

    Journal: Journal of Nuclear Medicine

    Article Title: Preirradiation of Spheroids with 225 Ac-Trastuzumab Improves Penetration of 225 Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails

    doi: 10.2967/jnumed.124.269273

    Figure Lengend Snippet: Comparison of BT474 experimental outgrowths taken from Howe et al. to MIRDcell (version 4.14)-predicted SFs as bar plot (A), linear regression plot (B), and Bland–Altman plot (C) (95% limit of agreement, −0.048 to 0.095). Predicted SFs shown were based on 225 Ac-trastuzumab in spheroids with no 225 Ac daughters present and 225 Ac-liposomes in spheroids with 225 Ac daughters present. 225 Ac-trastuzumab and 225 Ac-liposomes in medium both had 225 Ac daughters present. Bars on abscissa of panel A and legend for panels B and C are labeled to denote percentage of activity corresponding to 225 Ac-liposomes and 225 Ac-trastuzumab. For example, “L-100, A-0” is 100% 225 Ac-liposomes and 0% activity on trastuzumab antibodies. Error bars for experimental outgrowths correspond to SD. Final prediction uses penetration data for CFDA-SE liposomes after spheroids are exposed to 6.5 kBq/mL 225 Ac-trastuzumab for 50%/50% case; 70% and 30% 225 Ac-liposome cases use extrapolated/averaged penetration data shown in . For CFDA-SE liposomes, published penetration data that were used for old prediction did not involve pretreatment 225 Ac-trastuzumab. Only final predictions are shown in panels B and C.

    Article Snippet: The spheroids comprised the human epidermal growth factor receptor 2–positive human BT474 breast cancer cell line, obtained from the American Type Culture Collection.

    Techniques: Comparison, Liposomes, Labeling, Activity Assay

    Mean absorbed dose due to 225 Ac-trastuzumab (antibodies) and 225 Ac-liposomes (liposomes) in BT474 spheroids and medium for cells at various radial depths within 200-µm-radius spheroids (top). Below each graph, corresponding MIRDcell 3D slice representation of spheroid is shown for equatorial slices of spheroids. Dark red dots in equatorial slices represent living cells, whereas pink dots represent dead cells.

    Journal: Journal of Nuclear Medicine

    Article Title: Preirradiation of Spheroids with 225 Ac-Trastuzumab Improves Penetration of 225 Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails

    doi: 10.2967/jnumed.124.269273

    Figure Lengend Snippet: Mean absorbed dose due to 225 Ac-trastuzumab (antibodies) and 225 Ac-liposomes (liposomes) in BT474 spheroids and medium for cells at various radial depths within 200-µm-radius spheroids (top). Below each graph, corresponding MIRDcell 3D slice representation of spheroid is shown for equatorial slices of spheroids. Dark red dots in equatorial slices represent living cells, whereas pink dots represent dead cells.

    Article Snippet: The spheroids comprised the human epidermal growth factor receptor 2–positive human BT474 breast cancer cell line, obtained from the American Type Culture Collection.

    Techniques: Liposomes

    MIRDcell (version 4.16) AI–predicted minimum number of decays necessary to achieve target SF < 0.0001 in BT474 spheroids treated with 225 Ac-trastuzumab (antibodies), 225 Ac-liposomes (liposomes), or combination thereof. 225 Ac daughters were assumed to migrate away from 225 Ac-trastuzumab and to remain near 225 Ac-liposomes within spheroid. MIRDcell AI was limited to maximum molar activity of 10 6 GBq/mol for both drugs and lower limit of 1.17 × 10 5 GBq/mol for antibodies only. No bar appearing for antibodies indicates that 225 Ac-trastuzumab alone could not achieve target SF. When optimized molar activities for combined therapy and liposome-only therapy were checked in Monte Carlo–based MIRDcell simulation, zero cell survivors were achieved for both therapies although liposomes required more total decays to achieve same result. “Liposome with preirradiation” indicates use of penetration profiles after preirradiation with 225 Ac-trastuzumab as in 50%/50% case, and “Liposome without preirradiation” indicates use of liposome penetration profile without preirradiation as in 100% 225 Ac-liposomes case.

    Journal: Journal of Nuclear Medicine

    Article Title: Preirradiation of Spheroids with 225 Ac-Trastuzumab Improves Penetration of 225 Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails

    doi: 10.2967/jnumed.124.269273

    Figure Lengend Snippet: MIRDcell (version 4.16) AI–predicted minimum number of decays necessary to achieve target SF < 0.0001 in BT474 spheroids treated with 225 Ac-trastuzumab (antibodies), 225 Ac-liposomes (liposomes), or combination thereof. 225 Ac daughters were assumed to migrate away from 225 Ac-trastuzumab and to remain near 225 Ac-liposomes within spheroid. MIRDcell AI was limited to maximum molar activity of 10 6 GBq/mol for both drugs and lower limit of 1.17 × 10 5 GBq/mol for antibodies only. No bar appearing for antibodies indicates that 225 Ac-trastuzumab alone could not achieve target SF. When optimized molar activities for combined therapy and liposome-only therapy were checked in Monte Carlo–based MIRDcell simulation, zero cell survivors were achieved for both therapies although liposomes required more total decays to achieve same result. “Liposome with preirradiation” indicates use of penetration profiles after preirradiation with 225 Ac-trastuzumab as in 50%/50% case, and “Liposome without preirradiation” indicates use of liposome penetration profile without preirradiation as in 100% 225 Ac-liposomes case.

    Article Snippet: The spheroids comprised the human epidermal growth factor receptor 2–positive human BT474 breast cancer cell line, obtained from the American Type Culture Collection.

    Techniques: Liposomes, Activity Assay

    Figure 2. Characterization of Lapatinib-resistant BT474 cell variants. (A) Cell viability was evaluated by the MTT assay; BT474 (parental), BT474LapRV1, and BT474LapRV2 cells were treated with increasing concentrations of Lap for 48 h. Each data point is the mean of three independent experiments ± SD. IC50 values for Lap treatment. (B) Colony formation assay of parental and Lap-resistant BT474LapRV1

    Journal: International journal of molecular sciences

    Article Title: Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.

    doi: 10.3390/ijms26083763

    Figure Lengend Snippet: Figure 2. Characterization of Lapatinib-resistant BT474 cell variants. (A) Cell viability was evaluated by the MTT assay; BT474 (parental), BT474LapRV1, and BT474LapRV2 cells were treated with increasing concentrations of Lap for 48 h. Each data point is the mean of three independent experiments ± SD. IC50 values for Lap treatment. (B) Colony formation assay of parental and Lap-resistant BT474LapRV1

    Article Snippet: The BT474 human breast cancer cells (ATCC), BT474LapRV1, and BT474LapRV2 cell variants were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 μg/mL), and amphotericin B (0.25 μg/mL) in a 5% CO2 incubator at 37 ◦C.

    Techniques: MTT Assay, Colony Assay

    Figure 3. Cryptotanshinone (Cry) maintains chemoresistance in Lapatinib-resistant BT474 cell vari- ants. Cell viability tested by MTT assay; (A) Parental cells (BT474) were treated with increasing Cry concentrations (0–20 µM) for 48 h; (B) Parental, BT474LapRV1, and BT474LapRV2 cells were incubated with increasing Lap concentrations and 9 µM Cry for 48 h. Each data point is the mean of three independent experiments ± SD. (C) Immunoblot analyses of HER2 and p-HER2 in cells treated with 0.3 µM of Lap and Cry (9 µM) in cell variants. Densitometry analysis of p-HER2 (D) and HER2 (E) after β-actin normalization; black bar without treatment; grey bar Lap treatment; orange bar Lap plus Cry treatment. Results are presented as the mean of three experiments ± SD. * p < 0.05; ** p < 0.01; **** p < 0.001. (F) Docking of lapatinib in the HER2 tyrosine kinase domain (PDB 3PP0). HER2 is shown in beige and lapatinib in magenta.

    Journal: International journal of molecular sciences

    Article Title: Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.

    doi: 10.3390/ijms26083763

    Figure Lengend Snippet: Figure 3. Cryptotanshinone (Cry) maintains chemoresistance in Lapatinib-resistant BT474 cell vari- ants. Cell viability tested by MTT assay; (A) Parental cells (BT474) were treated with increasing Cry concentrations (0–20 µM) for 48 h; (B) Parental, BT474LapRV1, and BT474LapRV2 cells were incubated with increasing Lap concentrations and 9 µM Cry for 48 h. Each data point is the mean of three independent experiments ± SD. (C) Immunoblot analyses of HER2 and p-HER2 in cells treated with 0.3 µM of Lap and Cry (9 µM) in cell variants. Densitometry analysis of p-HER2 (D) and HER2 (E) after β-actin normalization; black bar without treatment; grey bar Lap treatment; orange bar Lap plus Cry treatment. Results are presented as the mean of three experiments ± SD. * p < 0.05; ** p < 0.01; **** p < 0.001. (F) Docking of lapatinib in the HER2 tyrosine kinase domain (PDB 3PP0). HER2 is shown in beige and lapatinib in magenta.

    Article Snippet: The BT474 human breast cancer cells (ATCC), BT474LapRV1, and BT474LapRV2 cell variants were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 μg/mL), and amphotericin B (0.25 μg/mL) in a 5% CO2 incubator at 37 ◦C.

    Techniques: MTT Assay, Incubation, Western Blot

    Figure 4. The axis p70S6K-PDCD4 is activated in chemoresistant cells. Chemoresitant cell variants BT474LapRV1, BT474LapRV2, and BT474 cells were treated under the scheme of Lap (0.3 µM) and Cry (9 µM). Western blot characterization of p70SK6α and p-p70SK6α (A), p70SK6β, and PDCD4 (B). (C) Densitometry analysis of PDCD4; black bar without treatment; grey bar Lap treatment; orange bar Lap plus Cry treatment; results are reported as the mean ± SD (n = 3) and expressed as normalized levels against β-actin. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Journal: International journal of molecular sciences

    Article Title: Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.

    doi: 10.3390/ijms26083763

    Figure Lengend Snippet: Figure 4. The axis p70S6K-PDCD4 is activated in chemoresistant cells. Chemoresitant cell variants BT474LapRV1, BT474LapRV2, and BT474 cells were treated under the scheme of Lap (0.3 µM) and Cry (9 µM). Western blot characterization of p70SK6α and p-p70SK6α (A), p70SK6β, and PDCD4 (B). (C) Densitometry analysis of PDCD4; black bar without treatment; grey bar Lap treatment; orange bar Lap plus Cry treatment; results are reported as the mean ± SD (n = 3) and expressed as normalized levels against β-actin. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Article Snippet: The BT474 human breast cancer cells (ATCC), BT474LapRV1, and BT474LapRV2 cell variants were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 μg/mL), and amphotericin B (0.25 μg/mL) in a 5% CO2 incubator at 37 ◦C.

    Techniques: Western Blot

    Figure 6. Cry induces estrogen receptor (ERα) down-regulation. (A) Expression levels of ERα and Bcl-xL under joint treatment of Lap (0.3 µM) and Cry (9 µM) in BT474, BT474LapRV1, and BT474LapRV2

    Journal: International journal of molecular sciences

    Article Title: Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.

    doi: 10.3390/ijms26083763

    Figure Lengend Snippet: Figure 6. Cry induces estrogen receptor (ERα) down-regulation. (A) Expression levels of ERα and Bcl-xL under joint treatment of Lap (0.3 µM) and Cry (9 µM) in BT474, BT474LapRV1, and BT474LapRV2

    Article Snippet: The BT474 human breast cancer cells (ATCC), BT474LapRV1, and BT474LapRV2 cell variants were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 μg/mL), and amphotericin B (0.25 μg/mL) in a 5% CO2 incubator at 37 ◦C.

    Techniques: Expressing

    Figure 7. Dysregulation of survival pathways RAF-MEK-ERK in chemoresistance variants. (A) Under the scheme of Lap (0.3 µM) and Cry (9 µM) treatment, Western blot of B-Raf in BT474 and BT474LapRV2

    Journal: International journal of molecular sciences

    Article Title: Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.

    doi: 10.3390/ijms26083763

    Figure Lengend Snippet: Figure 7. Dysregulation of survival pathways RAF-MEK-ERK in chemoresistance variants. (A) Under the scheme of Lap (0.3 µM) and Cry (9 µM) treatment, Western blot of B-Raf in BT474 and BT474LapRV2

    Article Snippet: The BT474 human breast cancer cells (ATCC), BT474LapRV1, and BT474LapRV2 cell variants were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 μg/mL), and amphotericin B (0.25 μg/mL) in a 5% CO2 incubator at 37 ◦C.

    Techniques: Western Blot

    Figure 8. Chemoresistance is associated with optimized calcium management. (A) Effect of joint treat- ment Lap (0.3 µM) and Cry (9 µM) on PMCA1/4 expression in BT474 and BT474LapRV2 cells; (B) under the same scheme, densitometry analysis of PMCA1/4, results are reported as the mean ± SD (n = 3) and expressed as fold change regarding loading control; * p < 0.05, ** p < 0.01 with regard to control. (C) Quantification of intracellular [Ca2+] under Lap and Cry treatments in BT474 and BT474LapRV2

    Journal: International journal of molecular sciences

    Article Title: Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.

    doi: 10.3390/ijms26083763

    Figure Lengend Snippet: Figure 8. Chemoresistance is associated with optimized calcium management. (A) Effect of joint treat- ment Lap (0.3 µM) and Cry (9 µM) on PMCA1/4 expression in BT474 and BT474LapRV2 cells; (B) under the same scheme, densitometry analysis of PMCA1/4, results are reported as the mean ± SD (n = 3) and expressed as fold change regarding loading control; * p < 0.05, ** p < 0.01 with regard to control. (C) Quantification of intracellular [Ca2+] under Lap and Cry treatments in BT474 and BT474LapRV2

    Article Snippet: The BT474 human breast cancer cells (ATCC), BT474LapRV1, and BT474LapRV2 cell variants were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 μg/mL), and amphotericin B (0.25 μg/mL) in a 5% CO2 incubator at 37 ◦C.

    Techniques: Expressing, Control

    Figure 9. NF-κB down-regulation is associated with chemoresistance. (A) Expression of the targets NF-κB and C-Myc in BT474 cells and brain tissue. (B) Effect of the Lap (0.3 µM) and Cry (9 µM) joint treatment on the expression of NF-κB and C-Myc in BT474 and BT474LapRV2 cells; (C) Under the same scheme, densitometry analysis of NF-κB, results are reported as the mean ± SD (n = 3) and expressed as fold change regard to loading control; * p < 0.05, ** p < 0.01, and *** p < 0.005 with regard to control. (D) Detection of PKCε under Lap and Cry treatments in BT474 and BT474LapRV2 cells. β-actin and GAPDH were used as a loading control. Bar colors represent the different treatments.

    Journal: International journal of molecular sciences

    Article Title: Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.

    doi: 10.3390/ijms26083763

    Figure Lengend Snippet: Figure 9. NF-κB down-regulation is associated with chemoresistance. (A) Expression of the targets NF-κB and C-Myc in BT474 cells and brain tissue. (B) Effect of the Lap (0.3 µM) and Cry (9 µM) joint treatment on the expression of NF-κB and C-Myc in BT474 and BT474LapRV2 cells; (C) Under the same scheme, densitometry analysis of NF-κB, results are reported as the mean ± SD (n = 3) and expressed as fold change regard to loading control; * p < 0.05, ** p < 0.01, and *** p < 0.005 with regard to control. (D) Detection of PKCε under Lap and Cry treatments in BT474 and BT474LapRV2 cells. β-actin and GAPDH were used as a loading control. Bar colors represent the different treatments.

    Article Snippet: The BT474 human breast cancer cells (ATCC), BT474LapRV1, and BT474LapRV2 cell variants were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 μg/mL), and amphotericin B (0.25 μg/mL) in a 5% CO2 incubator at 37 ◦C.

    Techniques: Expressing, Control